Novavax shows an effectiveness of 89.3% against Covid-19.
Following phase 3 trials in the UK, new vaccines also available Effective against new variants of viruses discovered in the UK.
The UK has ordered 60 million doses of vaccines, which are expected to be distributed later this year. First, the vaccine must be approved by the drug and healthcare product regulatory body.
Novavax CEO Stan Erck said the outcome of the UK trial was “spectacular.” The vaccine will be produced at Stockton-on-Tei.
“The results of the UK trial for Novavax vaccine look very promising. We welcome the news that the company is planning to submit data to regulators,” said Business Secretary Kwasi Kwarteng. . “The UK has moved rapidly to source 60 million doses from Novavax. We are pleased to see that the majority of the vaccines will be manufactured at Teesside and will be delivered if approved for use. .”
Health Secretary Matt Hancock said: “This is positive news and if approved by drug regulators, the Novavac vaccine will significantly boost our vaccination program and another weapon in weapon to beat this terrible virus. I am proud to be at the forefront of another medical breakthrough. I would like to thank the incredible scientists and researchers, as well as the tens of thousands of selfless volunteers who have been on the park in clinical trials. Masu.”
Already, the UK has deployed vaccine doses from Oxford University and AstraZeneca, while another AstraZeneca is the final vaccine from Pfizer and BioNTech and pharmaceutical company Moderna. The prime minister said that by mid-February, 15 million people in Britain would have received their first injection.
